Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Advanced Cancer Clinical Trial

Official title:

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Docetaxel Lipid Microsphere for Injection in Cancer Patients Receiving Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01611961
• Other study ID #: SYPHU-DT-LM-01
• Status: Recruiting
• Phase: Phase 1
• First received: May 29, 2012
• Last updated: September 27, 2014
• Start date: August 2012
• Est. completion date: December 2014

Study information

• Verified date: September 2014
• Source: Shenyang Pharmaceutical University
• Contact: Yuankai Shi
• Phone: 86-10-87788121
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Docetaxel Lipid Microsphere (DT-LM) is a novel proprietary delivery system of docetaxel developed by Shenyang Pharmaceutical University. In this Phase I study, the DT-LM was evaluated for the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) in patients with advance solid tumors. It was also evaluated for pharmacokinetic and anti-tumor effects of DT-LM compared to commerical docetaxel.

Description:

Docetaxel (currently marketed as Taxotere®), given by intravenous or intraperitoneal injection, has contributed significantly to the treatment of a variety of malignancies, such as ovarian, breast, gastric, and non-small-cell lung cancer (NSCLC), as well as head and neck cancer and some other cancers. In the preclinical, DT-LM showed reduced toxicity (especially myelosuppression）and comparable therapeutic efficacy. In clinic, it is believed that DT-LM will offer fewer side effects to the patient at similar doses, and possibly greater effectiveness when used at higher doses. DT-LM could not only avoid the serious hypersensitivity reactions caused by Tween 80, but also be stable, safe and convenient for clinical administration.

This study is designed to determine the following:

• The maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of DT-LM.

• The pharmacokinetics of docetaxel following intravenous administration of DT-LM.

• Any anti-tumor effects of DT-LM.

Controlled trial is also carrying out to reveal the differences in safety, pharmacokinetics and pharmacodynamics between DT-LM and Taxotere.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: December 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age > 18 and < 65, with ECOG performance status 0-1,and Life expectancy of more than 3 months.

2. Have advanced (local and/or metastatic) histologically documented cancer considered unresponsive to available conventional modalities or treatments.

3. Have recovered from acute toxicities of prior treatment:

• 4 weeks must have elapsed since receiving any investigational agent.

• 4 weeks must have elapsed since receiving any radiotherapy, or treatment with cytotoxic or biologic agents (=6 weeks for mitomycin or nitrosoureas).

• 4 weeks must have elapsed since any prior surgery.

4. Be in adequate condition as evidenced by the following clinical laboratory values:

• Absolute neutrophil count (ANC) =1,500/mm3.

• Platelets = 80,000/mm3.

• Hemoglobin = 9.0 g/dL.

• WBC = 4,000/mm3.

• Total bilirubin = 2.5 x institutional upper limit normal (ULN).

• Transaminases AST (SGOT) and ALT (SGPT) = 1.5 times ULN or = 5 times ULN (liver metastasis).

• Serum creatinine = 1.2 times ULN, blood urea nitrogen= 1.2 times ULN.

5. both female and male patients must use adequate methods of contraception.

6. Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board (IRB)/Independent Ethics Committee approved written informed consent form prior to treatment.

Exclusion Criteria:

1. Intolerance to any antineoplastic agents belonging to the taxoid family.

2. having failed a docetaxel-containing regimen or Having known non-controllable hypersensitivity to docetaxel or lipid microsphere.

3. Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease).

4. Unstable or uncontrolled cardiac disease or hypertension.

5. With other serious internal diseases, uncontrolled infection or uncontrolled diabetes.

6. With Symptomatic brain metastasis not controlled.

7. Having pre-existing clinically significant neuropathy (NCI CTCAE Grade = 2 neuromotor or Grade = 2 neurosensory) except for abnormalities due to cancer.

8. Currently receiving any other standard or investigational treatment for cancer or any other investigational agent for any indication.

9. Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.

10. Female patients who are pregnant or breast-feeding.

11. Unwilling or unable to follow protocol requirements.

12. With history of serious allergic or allergy.

13. Not fit for the clinical trial judged by the investigator.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Cancer

Intervention

Drug:
• DT-LM
Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
• docetaxel
Intravenous infusion, 3 dose levels:60, 75, and 90 mg/m2, Every 3 weeks

Locations

Country	Name	City	State
China	Cancer Institute & Hospital, Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shenyang Pharmaceutical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The safety and tolerability	This Phase I, open-label, control,dose-escalation study was designed to determine the maximum tolerated dose (MTD) of DT-LM in patients with advanced cancer. DT-LM was administered by intravenous infusion, over 1 hour, once every 21 days until occurrence of disease progression or toxicity requiring early treatment discontinuation. Dose escalation was not done until the safety and tolerability at a given dose level has been confirmed.	one year	Yes
Secondary	Assessment of pharmacokinetics of DT-LM and Taxotere: AUC and Cmax	The patients were evaluated for pharmacokinetic profile of DT-LM and Taxotere upto 48 hours post treatment after cycle 1 and cycle 2,respectively.	one year	No
Secondary	Objective tumour response according to RECIST	The anti-tumor effects were evaluated after every two cycles of treatment.	one year	No